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Abstract
GLUCOCORTICOIDS are steroid hormones that strongly influence intermediary carbohydrate metabolism by increasing the
transcription rate of glucose-6-phosphatase (G6Pase), a key enzyme of gluconeogenesis, and suppress the immune system
through the glucocorticoid receptor (GR). The liver X receptors (LXRs), on the other hand, bind to cholesterol metabolites,
heterodimerize with the retinoid X receptor (RXR), and regulate the cholesterol turnover, the hepatic glucose metabolism by
decreasing the expression of G6Pase, and repress a set of inflammatory genes in immune cells. Since the actions of these
receptors overlap with each other, we evaluated the crosstalk between the GR- and LXR-mediated signaling systems.
Transient transfection-based reporter assays and gene silencing methods using siRNAs for LXRs showed that
overexpression/ligand (GW3965) activation of LXRs/RXRs repressed GR-stimulated transactivation of certain glucocorticoid
response element (GRE)-driven promoters in a gene-specific fashion. Activation of LXRs by GW3965 attenuated
dexamethasone-stimulated elevation of circulating glucose in rats. It also suppressed dexamethasone-induced mRNA
expression of hepatic glucose-6-phosphatase (G6Pase) in rats, mice and human hepatoma HepG2 cells, whereas
endogenous, unliganded LXRs were required for dexamethasone-induced mRNA expression of phosphoenolpyruvate
carboxylase. In microarray transcriptomic analysis of rat liver, GW3965 differentially regulated glucocorticoid-induced
transcriptional activity of about 15% of endogenous glucocorticoid-responsive genes. To examine the mechanism through
which activated LXRs attenuated GR transcriptional activity, we examined LXRa/RXRa binding to GREs. Endogenous LXRa/
RXRa bound GREs and inhibited GR binding to these DNA sequences both in in vitro and in vivo chromatin
immunoprecipitation assays, while their recombinant proteins did so on classic or G6Pase GREs in gel mobility shift assays.
We propose that administration of LXR agonists may be beneficial in glucocorticoid treatment- or stress-associated
dysmetabolic states by directly and gene-specifically attenuating the transcriptional activity of the GR on glucose and/or
lipid metabolism.
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Introduction
GLUCOCORTICOIDS, steroid hormones produced by and
secreted from the adrenal cortex, are essential for the maintenance
of metabolic homeostasis both in the basal state and in response to
stress [1,2]. These hormones exert their actions in almost all tissues
and organs, and strongly influence intermediary carbohydrate,
lipid and protein metabolism [3]. For example, glucocorticoids
induce gluconeogenesis by increasing the transcription rates of its
key enzymes glucose-6-phosphatase (G6Pase), which mediates the
final step of both gluconeogenesis and glycogenolysis [4] and
phosphoenolpyruvate carboxykinase (PEPCK), which catalyzes
the conversion of oxaloacetate to phosphoenolpyruvate [5,6]. In
addition to these metabolic effects, glucocorticoids also demon-
strate strong suppressive effects on the immune system that makes
them important therapeutic agents in the treatment of allergic,
autoimmune, inflammatory and lymphoproliferative diseases [7].
However, chronic excess of glucocorticoid secretion, as occurs in
endogenous Cushing syndrome and during chronic stress, or
chronic administration of glucocorticoids for the treatment of
responsive diseases, may lead to carbohydrate intolerance or frank
diabetes, as well as to dyslipidemia (high VLDL- and LDL-
cholesterol and low HDL-cholesterol), all detrimental conditions
leading to atherosclerosis and cardiovascular diseases [8,9,10].
The biologic actions of circulating glucocorticoids are transmit-
ted to the nucleus of cells by the ubiquitously expressed
cytoplasmic/nuclear glucocorticoid receptor (GR), a member of
the nuclear receptor superfamily that is comprised by over 130
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of 777 amino acids and has three major functional domains, the
N-terminal (NTD) ‘‘immunogenic’’, middle DNA-binding (DBD)
and C-terminal ligand-binding (LBD) domains [11]. Upon
hormone binding, the glucocorticoid-GR complex translocates
from the cytoplasm into the nucleus and binds its specific DNA
recognition sequences, the glucocorticoid response elements
(GREs), located in the regulatory regions of glucocorticoid-
responsive genes or interacts with other transcription factors to
modulate the latter’s transcriptional activities on their target genes
by attracting numerous co-factor molecules and protein complexes
to the respective transcription initiation complexes [11,12].
The liver X receptors (LXRs), which also belong to the nuclear
receptor superfamily, mediate the biologic actions of various lipids,
such as the cholesterol metabolites oxysterols, and also prostanoids
and some fatty acids, by directly binding to these molecules [13].
LXRs exist as two subtypes, LXRa and LXRb, which display
distinct patterns of tissue expression: LXRa is primarily expressed
in the liver, intestine, adipose tissue, kidney and immune
macrophages, whereas LXRb is distributed ubiquitously [14].
Once LXRs bind their lipid ligands, they form a heterodimer with
the retinoid X receptor (RXR), and stimulate the transcription of
an array of genes involved in the absorption, efflux, transport, and
excretion of cholesterol and other lipids [13,14,15]. LXRs also
regulate glucose metabolism by decreasing the expression of its
rate-limiting enzymes G6Pase and PEPCK [16,17,18], and have
anti-inflammatory activity by repressing a set of inflammatory
genes in macrophages and other immune cells [19]. These pieces
of evidence indicate that the biologic actions of the GR and the
LXRs may overlap with each other and that LXR activation may
moderate the detrimental actions of chronically elevated gluco-
corticoids on carbohydrate and lipid metabolism. The purpose of
this study is to evaluate the possible crosstalk between the GR- and
LXR-mediated signaling systems by testing the effects of LXR
activation on GR transcriptional activities and the ability of the
former to moderate the effects of the latter.
Results
LXRs suppress dexamethasone-stimulated GR
transcriptional activity on the MMTV promoter in HCT116
cells
To examine impact of LXRs on GR-mediated transcriptional
activity, we first expressed human GR in HCT116 cells that do not
express the endogenous molecule [20] together with the
glucocorticoid-responsive mouse mammary tumor virus (MMTV)
promoter-driven luciferase reporter gene (pMMTV-Luc), in the
presence or absence of increasing amounts of the LXRa-
expressing plasmid along with that of its obligate heterodimer
partner RXRa. LXRa/RXRa over-expression strongly sup-
pressed the transcriptional activity of the MMTV promoter in a
dexamethasone-dependent fashion (Fig. 1A, upper panel). A
significant decrease of 30% was observed in the presence of
0.03 mg of LXRa/RXRa-expressing plasmids, reaching up to
86% in the presence of 1 mg of plasmids expressing these
heterodimer components. The observed negative effect was totally
reversed by increasing amounts of the GR-expressing plasmid,
suggesting that there may be competition between LXRa/RXRa
and GR (Fig. 1B, upper panel). In these experiments, we measured
the relative mRNA expression of LXRa and GR using the acidic
ribosomal phosphoprotein P0 (RPLP0) as an internal control,
calculated relative ratios of LXRa mRNA vs. GR mRNA, and
confirmed that the transcriptional changes observed were due to
alteration in the expressions of these NRs (Fig. 1A and 1B, lower
panels). The suppressive effect of LXRa/RXRa on dexametha-
sone-stimulated transcriptional activity of the MMTV promoter
was observed in the absence of LXR-specific ligands (Fig. 1 A and
B, upper panels), consistent with a previous report that LXRs are
activated just by heterodimerization in the absence of ligand, via a
mechanism termed ‘dimerization-induced activation’ [21]. This is
a unique activation mechanism for LXRs, which has not been
described for the other nuclear receptors [21]. We further tested
the effect of LXR ligands on GR-induced transcriptional activity,
by over-expressing LXRa or LXRb along with RXRs in HCT116
cells and by treating these cells with or without different LXR
ligands, such as the natural ligand 22-R hydroxycholesterol (22-R-
HC) and the two synthetic ligands T0901317 and GW3965.
T0901317 activates LXRs but also other nuclear receptors, such
as the pregnane X receptor (PXR), whereas GW3965 is a specific
ligand for LXRs [22,23]. Activation of over-expressed LXRa
(Fig. 1C, left panel)o rb (Fig. 1C, right panel) by these ligands
enhanced LXR/RXR-mediated repression of GR-induced tran-
scriptional activity on the MMTV promoter by more than 50%
(Fig. 1C).
LXRa regulates GR-mediated transcriptional activity in a
gene promoter-specific fashion
We next investigated the effect of LXRa on the transactiva-
tional activity of GR on two glucocorticoid-responsive genes, the
phosphoenolpyruvate carboxykinase (PEPCK) and the glucocorti-
coid-inducible leucine zipper protein (GILZ), both of which
contain functional GREs within their promoter regions [6,24].
We transfected HCT116 cells with GR-expressing plasmid along
with the PEPCK or GILZ promoter-driven luciferase reporter,
pPEPCK-Luc (Fig. 2A) or pGILZ-Luc (Fig. 2B), in the presence or
absence of LXRa/RXRa over-expression. GR stimulated the
transcriptional activity of these promoter constructs in a
dexamethasone-dependent fashion. Overexpression of LXRa/
RXRa repressed dexamethasone-stimulated transcriptional activ-
ity of the PEPCK promoter by approximately 50%, with no
significant change after addition of GW3965 (Fig. 2A), while no
significant suppressive effect was observed on dexamethasone-
stimulated transcriptional activity of the GILZ promoter (Fig. 2B).
We further examined the effect of LXRa/RXRa on the
transrepressive effect of the GR (Fig. 2C) on a nuclear factor kB
(NF-kB)-responsive reporter gene in HCT116 cells by over-
expressing the NF-kB components p65 and p50 in the presence of
the kB-response element (RE)-driven reporter plasmid. Overex-
pression of p65/p50 stimulated the activity of this promoter, while
dexamethasone suppressed it in a GR expression-dependent
fashion. Overexpression of LXRa/RXRa did not influence GR-
mediated repression of p65/p50-induced transcriptional activity
(Fig. 2C), suggesting that LXRa/RXRa does not affect the
transrepressive effect of GR caused via physical interaction with
other transcription factors. Taken together, these findings indicate
that LXRa/RXRa affect the transactivating, but not the
transrepressive activity of the GR in a gene-specific fashion in
HCT116 cells.
LXRs differentially regulate dexamethasone-induced
mRNA expression of endogenous glucocorticoid-
responsive genes in HepG2 cells
We next examined the effect of specific LXR ligand GW3965
on dexamethasone-stimulated mRNA expression of endogenous
glucocorticoid-responsive genes in HepG2 cells. GW3965 com-
pletely attenuated dexamethasone-induced mRNA expression of
the G6Pase (Fig. 3A, white bars) and PEPCK (Fig. 3B, white bars)
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e26751Figure 1. LXRs repress GR-induced transcriptional activity in HCT116 cells. A. Over-expression of LXRs strongly suppresses dexamethasone-
stimulated transcriptional activity of the MMTV promoter in HCT116 cells. HCT116 cells were transfected with pRShGRa together with pMMTV-Luc
and pGL4.73[hRluc/SV40], and increasing amounts of pCMX-hLXRa and pCMX-hRXRa (0.03–1 mg), and were incubated in the presence or absence of
10
26 M dexamethasone. Upper panel: Bars represent mean 6 S.E. values of the firefly luciferase activity normalized for the renilla luciferase activity in
the presence or absence of 10
26 M dexamethasone. *: p,0.01, n.s.: not significant, compared to the condition treated with dexamethasone in the
absence of LXRa/RXRa. Lower panel: Total RNA from transfected HCT116 cells was harvested and relative mRNA expression of LXRa and GR were
measured with the SYBR-Green real-time PCR. Bars represent mean 6 S.E. values of the relative ratios of LXRa mRNA vs. GR mRNA using RPLP0 as an
internal control. Dex: dexamethasone, RLA: relative luciferase activity. B. Over-expression of GR reverses the negative effect of LXRa/RXRa on
dexamethasone-stimulated transcriptional activity of the MMTV promoter. HCT116 cells were transfected with increasing amounts of pRShGRa (0.25–
1.5 mg) together with pMMTV-Luc, pGL4.73[hRluc/SV40], pCMX-hLXRa and pCMX-hRXRa, and were incubated in the presence or absence of 10
26 M
dexamethasone. Upper panel: Bars represent mean 6 S.E. values of the firefly luciferase activity normalized for the renilla luciferase activity in the
presence or absence of 10
26 M dexamethasone. *: p,0.01, n.s.: not significant, compared to the condition treated with dexamethasone in the
absence of LXRa/RXRa. Lower panel: Total RNA from transfected HCT116 cells was harvested and relative mRNA expression of LXRa and GR were
measured with the SYBR-Green real-time PCR. Bars represent mean 6 S.E. values of the relative ratios of LXRa vs. GR mRNA using RPLP0 as an internal
control. Dex: dexamethasone, RLA: relative luciferase activity. C. Over-expression of LXRa (left panel) or LXRb (right panel) in the presence of indicated
LXR ligand suppresses dexamethasone-stimulated GR transcriptional activity on the MMTV promoter. HCT116 cells were transfected with pRShGRa,
pMMTV-Luc and pGL4.73[hRluc/SV40] together with pCMX-hLXRa or -mLXRb and pCMX-mRXRa, and were incubated in the presence or absence of
10
26 M dexamethasone and/or indicated LXR ligands. Bars represent mean 6 S.E. values of the firefly luciferase activity normalized for the renilla
luciferase activity. *: p,0.01 compared to the condition treated with dexamethasone in the absence of LXR ligand. Dex: dexamethasone, RLA: relative
luciferase activity, 22-R-HC: 22-R-hydroxycholesterol.
doi:10.1371/journal.pone.0026751.g001
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mRNA expression of the GILZ gene (Fig. 3C, white bars). When
GW3965 was added, we observed a slight but significant decrease
of G6Pase mRNA expression (Fig. 3A, white bars), as well as a
significant increase of LXRa mRNA expression (Fig. 3E, white
bars) consistent with previous reports [17,25]. GW3965 strongly
increased mRNA expression of the LXR-responsive ATP-binding
cassette sub-family G member 1 (ABCG1) gene [26], indicating
that this compound efficiently activated LXRs (Fig. 3D, white
bars). To demonstrate the specificity of the observed GW3965
effect, we knocked down the expression of both LXRa and LXRb
with their respective siRNAs (Fig. 3, black bars). Transfection of
HepG2 cells with these siRNAs efficiently suppressed mRNA and
protein expression of LXRa and b (Fig. 3E and 3F, black bars, and
3H), and completely abolished GW3965-induced suppression of
dexamethasone-mediated mRNA expression of the G6Pase and
PEPCK genes (Fig. 3A and 3B, black bars), indicating that
activation of LXRs by GW3965 directly mediates the negative
effect of this compound on GR-induced transcriptional activity on
the endogenous G6Pase and PEPCK genes. In contrast, LXRa/b
knockdown in itself attenuated dexamethasone-stimulated mRNA
expression of the PEPCK gene (Fig. 3B, black bars), suggesting that
endogenous LXRs are required for the optimum action of
dexamethasone on this gene in the absence of GW3965.
GW3965 did not alter mRNA expression of GR throughout the
experiment (Fig. 3G), and Western blots for LXRa and GR using
lysates obtained from HepG2 cells treated with vehicle, Dex and/
or GW3965 showed that transfection of HepG2 cells with LXRa
siRNA efficiently suppressed LXRa protein levels but not those of
the GR (Fig. 3H). In addition, Western blots for GR using nuclear
extracts of HepG2 cells treated with GW3965 and/or dexameth-
asone demonstrated that GW3965 did not influence dexametha-
sone-induced accumulation of GR in the nucleus (Fig. 3I). These
results further indicate that agonist-activated endogenous LXRs
suppress GR-induced transcriptional activity on natural glucocor-
ticoid-responsive genes in a gene-specific fashion in addition to the
artificial reporter assay system in which LXRs, GR and
glucocorticoid-responsive promoters were exogenously introduced.
Figure 2. Over-expression of LXRa regulates dexamethasone-stimulated GR transcriptional activity in a gene promoter-specific
way. A and B. Over-expression of LXRa/RXRa suppresses dexamethasone-stimulated transcriptional activity of the PEPCK (A) but not the GILZ (B)
promoter. HCT116 cells were transfected with pPEPCK-luc (A) or pGILZ-Luc (B), together with pGL4.73[hRluc/SV40] and pRShGRa in the presence or
absence of pCMX-hLXRa and pCMX-hRXRa, and were incubated with or without 10
26 M dexamethasone and/or 10
26 M GW3965. Bars represent
mean 6 S.E. values of the firefly luciferase activity normalized for the renilla luciferase activity. *: p,0.01, n.s.: not significant between the two
conditions indicated. Dex: dexamethasone, RLA: relative luciferase activity. C. Over-expression of LXRa/RXRa does not affect dexamethasone-induced
repression of the transcriptional activity of NF-kB. HCT116 cells were transfected with (kB)3-Luc and pGL4.73[hRluc/SV40] in the presence or absence
of pRSV-RelA (p65)/pRSV-NF-kBI (p50), pRShGRa, and pCMX-hLXRa and pCMX-hRXRa, and were incubated with or without 10
26 M dexamethasone.
Bars represent mean 6 S.E. values of the firefly luciferase activity normalized for the renilla luciferase activity. *: p,0.01, n.s.: not significant, compared
to the condition obtained in the absence of p65/p50 and dexamethasone treatment, or between the two conditions indicated. Dex: dexamethasone,
RLA: relative luciferase activity.
doi:10.1371/journal.pone.0026751.g002
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stimulate mRNA expression of some glucocorticoid-responsive
genes. Our results also suggest that LXRs influence the
transcriptional activity of GR inside the nucleus via a molecular
mechanism that does not include modification of GR expression
and nuclear translocation.
GW3965 attenuates dexamethasone-induced elevation
of circulating glucose levels in rats and suppresses
G6Pase mRNA expression by this steroid in rat and
mouse livers
Since LXRs strongly suppressed GR-induced mRNA expres-
sion of the G6Pase and PEPCK genes in HepG2 cells, and they play
a key role in glucose metabolism, we examined the effect of
GW3965 on dexamethasone-induced hyperglycemia in rats, as
well as G6Pase mRNA expression in rat and mouse livers.
Dexamethasone increased blood glucose levels by ,40% in rats
after 24 hours of the injection, while GW3965 strongly prevented
the elevation caused by this steroid (Fig. 4A). GW3965 completely
attenuated dexamethasone-induced mRNA expression of G6Pase
in the rat livers (Fig. 4B). Importantly, LXRa/b knockout mice
lost GW3965-induced suppression of G6Pase mRNA induction by
dexamethasone in the liver, while wild type mice demonstrated a
GW3965-mediated suppression similar to that of rats (Fig. 4B and
4C). GW3965 completely attenuated dexamethasone-induced
mRNA expression of the PEPCK gene in the livers of wild type
Figure 3. Ligand activation of endogenous LXRs differentially regulates dexamethasone-induced mRNA expression of
glucocorticoid-responsive genes in a gene-specific fashion. A, B, C, D, E, F and G. HepG2 cells were transfected with negative control
siRNA for luciferase GL2 (white bars) or siRNAs for LXRa/b (black bars), and were treated with or without 10
26 M dexamethasone and/or 10
26 M
GW3965. Total RNA was harvested and mRNA levels of G6Pase (A), PEPCK (B), GILZ (C), ABCG1 (D), LXRa (E), LXRb (F) and GR (G) were measured with
the SYBR-Green real-time PCR. Bars represent mean 6 S.E. values of the fold induction of mRNA expression. *: p,0.01, n.s.: not significant compared
to the condition transfected with the control siRNA in the presence of dexamethasone or between the two conditions indicated. Dex:
dexamethasone. H. siRNAs for LXRa suppress expression of LXRa protein in HepG2 lysates. HepG2 cells were transfected with negative control siRNA
for luciferase GL2 or siRNAs for LXRa, and were treated with or without 10
26 M dexamethasone and/or 10
26 M GW3965 for 24 hours, and cells
lysates were prepared. hLXRa (upper panel), hGR (middle panel) and hb-actin (lower panel) were visualized with their specific antibodies in Western
lots. I. Ligand activation of endogenous LXRs does not influence dexamethasone-induced translocation of GR from the cytoplasm into the nucleus.
HepG2 were treated for 2 hours with or without 10
26 M dexamethasone and/or 10
26 M GW3965. Whole cell lystates and nuclear extracts were run
on 4–20% SDS-PAGE gels, blotted to nitrocellulose membranes and hGR (upper panel: nuclear GR, middle panel: whole cell GR) and hHSP4 (lower
panel) were visualized with their specific antibodies in Western blots.
doi:10.1371/journal.pone.0026751.g003
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lated mRNA expression of this gene in the absence of GW3965
(Fig. 4D). These results are consistent with our findings obtained in
HepG2 cells transfected with LXRa/b siRNAs, further confirm-
ing that endogenous LXRs have dual effects on GR-stimulated
mRNA expression of the PEPCK gene. Taken together, these
results indicate that LXRs repress GR-induced transcriptional
activity at the animal level, attenuating elevations of circulating
glucose levels and suppressing expression of liver G6Pase and
PEPCK mRNA stimulated by glucocorticoids.
LXRs differentially regulate GR-induced transcriptional
activity in rat liver in microarray analysis
To further address functional interaction between LXRs and
GR at a transcriptome level, we performed microarray analysis
using the Rat Genome 230 2.0 Tiled Array (Affymetrix Inc.) in
samples obtained from livers of rats treated with dexamethasone
and/or GW3965 (Fig. 5). Among ,15,000 genes successfully
analyzed, dexamethasone changed mRNA expression of 727
(,4.8%) genes, and GW3965 altered the expression of 141 genes
(,1%) (Fig. 5A), among which 77 genes were dexamethasone
unresponsive (Table S1). Dexamethasone and GW3965 shared 64
genes that are mostly implicated in immune and inflammatory
response pathways (Fig. 5A). Simultaneous treatment with
dexamethasone and GW3965 (Dex+GW3965) changed mRNA
expression of 523 genes implicated in different biological
pathways, among which 313 genes were also regulated by
dexamethasone alone (Fig. 5B). GW3965 treatment did not alter
mRNA expression of 202 genes out of these 313 common genes,
whereas the remaining 111 genes (,15% of the total 727
dexamethasone-regulated genes) showed an expression that was
significantly different from the dexamethasone treatment alone,
indicating that GW3965 influenced dexamethasone-induced
changes in these 111 genes. Of these 111 genes, GW3965
treatment altered mRNA expression of 45 (,6%) genes down-
regulated by dexamethasone, and 66 (,9%) genes up-regulated by
this steroid, indicating that GW3965 influences GR-induced
transactivation more frequently than transrepression. Further-
more, GW3965 treatment attenuated dexamethasone-induced
suppressive and enhancing effect on the mRNA expression of the
majority of the 111 genes (Tables S2 and S3). Numbers of the
genes in some specific biological pathways regulated by dexa-
methasone and/or GW3965 are also shown in Fig. 5E.
In contrast to the effect of GW3965 on GR-induced
transcriptional activity, only 26 genes out of 141 GW3965-
responsive genes were influenced by the addition of dexametha-
Figure 4. GW3965 attenuates dexamethasone-induced hyperglycemia in rats and represses dexamethasone-induced G6Pase
mRNA expression in mouse and rat livers and PEPCK mRNA expression in mouse livers. A. GW3965 attenuates dexamethasone-induced
increase of blood glucose levels in rats. Blood glucose levels were measured in rats treated with the compounds indicated. Bars represent mean 6
S.E. values of the blood glucose concentration. *: p,0.01, compared to the animals treated with dexamethasone or between the two conditions
indicated. Dex: dexamethasone. B, C and D. GW3965 suppresses dexamethasone-induced mRNA expression of glucocorticoid-responsive G6Pase in
the livers of rats (B), G6Pase and PEPCK in wild type, but not LXRa/b knockout mice (C and D). Rats, wild type (WT) and LXRa/b knockout mice were
orally gavaged for three days with GW3965, and were injected with dexamethasone or physiologic saline intramuscularly. Twenty-four hours after the
injection, Total RNA was harvested from their livers and mRNA levels of rat G6Pase (B), mouse G6Pase (C) and mouse PEPCK (D) were measured with
the SYBR-Green real-time PCR. Bars represent mean 6 S.E. values of the fold induction of mRNA expression against vehicle. *: p,0.01, n.s.: not
significant, compared to the animals treated with dexamethasone or between the two conditions indicated. Dex: dexamethasone, KO: knockout.
doi:10.1371/journal.pone.0026751.g004
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LXR actions is not as strong as that of LXRs on GR actions. To
examine whether the 72-hour GW3965 treatment alters GR
protein levels in the rat liver, we performed Western blots for GR
in the liver of rats treated for 72 hours, and found that GW3965
did not alter GR protein levels (Fig. 5D). . These results rule out
the possibility of GW3965 altering dexamethasone-induced gene
expression by affecting GR expression levels
In Table 1, we summarized the gene-selective effects of LXRs
on GR-induced transcriptional activity. We cited some of the
genes known to be associated with the transrepressive activity of
the GR, such as the stem cell factor (Scf), chemokine (C-C motif)
ligand 9 (Ccl9), interleukin 33 (Il33) and chemokine (C-X-C motif)
ligand 12 (Cxcl12) genes, which encode proteins that belong to the
family of cytokines involved in immunoregulatory and inflamma-
tory processes, and are often induced by proinflammatory stimuli
[27], the cyclin D1 gene (Ccnd1), a key regulator of cell
proliferation whose overexpression plays a role in tumorigenesis
[28], and the cytokine-inducible SH2-containing protein (Cish),
which belongs to the cytokine-induced STAT inhibitor (CIS)
family, whose members are induced by cytokines and act as
negative regulators of cytokine signaling [29]. Dexamethasone
down-regulated mRNA expression of all these genes, while
GW3965 did not significantly influence the suppressive effect of
dexamethasone on the mRNA expression of the Scf, Ccl9, Il33,o r
Cxcl12 genes; In contrast, GW3965 reversed the negative effect of
dexamethasone on the mRNAs of the Ccnd1 and Cish genes.
Dexamethasone up-regulated mRNA expression of the 6-phos-
phofructo-2-kinase/fructose-2,6-biphosphatase 1 (Pfkfb1) gene,
which encodes a protein functioning as an activator of glycolysis
and an inhibitor of gluconeogenesis, the Slc2a5 gene encoding the
glucose/fructose transporter protein member 5 (GLUT5) that
regulates glucose and fructose transport from the intestinal lumen
into the enterocytes [30,31], the G6Pase gene, the hexose-6-
phosphate-dehydrogenase (H6pdh) gene, encoding an enzyme
generating reduced nicotinamide adenine dinucleotide phosphate
(NADPH) that is required by 11b-hydroxysteroid dehydrogenase
type 1 (11b-HSD1) for the activation of glucocorticoids [32].
Activated GR also increased mRNA expression of the lipin 1
(Lpin1) and serine dehydratase (Sds) genes, as previously reported
[33]: The former encodes a member of the lipin enzyme family
that plays a role in human triglyceride metabolism and influences
glucose homeostasis in diverse organs and tissues, including the
liver [34], while the latter gene product converts serine to pyruvate
and is involved in gluconeogenesis [35]. GW3965 completely
suppressed dexamethasone-induced mRNA expression of G6Pase
and H6pd, and significantly repressed that of Lpin1 and Sds, while it
did not affect dexamethasone-mediated induction of Pfkfb1 and
Slc2a5 mRNA. In contrast, GW3965 significantly enhanced
dexamethasone-induced mRNA expression of the interferon-
induced protein 44 (Ifi44) and the 29-59 oligoadenylate synthetase
1A (Oas1a), both of which play key roles in innate immune
responses against viral infections [36,37]. We confirmed our
microarray results by examining in the reconstituted real-time
PCR assays mRNA expression of the Ccl9 and Cxcl12 genes, as
representatives of the genes down-regulated by dexamethasone
(Fig. 5F, upper panel), and the H6pd gene, as a representative of
genes up-regulated by this steroid (Fig. 5F, lower panel). Taken
together, these results are consistent with our findings obtained in
transient transfection-based reporter assays that LXRs regulate
GR-transcriptional activity in a gene-specific fashion.
LXRa/RXRa heterodimer competes with GR for binding
to GREs
To examine the mechanism(s) underlying LXR-induced
repression of GR transcriptional activity, we examined the effect
of LXRa/RXRa overexpression on the binding of GR to its DNA
recognition sequences GREs in vitro and in vivo (Fig. 6), granted that
we noticed in the transfection experiment that LXRa/RXRa and
GR competed with each other for dexamethasone-mediated
activation of the MMTV promoter (Fig. 1). In our in vitro GR/
GRE binding assay, nuclear GR extracted from HeLa cells bound
to the classic consensus immobilized GRE oligonucleotide in a
dexamethasone-dependent fashion, while free oligonucleotides
encoding wild type, but not mutated, GREs inhibited this binding
(Fig. 6A). Over-expression of LXRa/RXRa in these cells
attenuated dexamethasone-mediated association of GR to immo-
bilized GREs (Fig. 6A, upper panel). Overexpression of LXRa/
RXRa did not influence dexamethasone-induced accumulation of
GR in the nucleus in the samples used in our in vitro GR/GRE-
binding assay (Fig. 6A, lower panel). We next examined the effect of
over-expressed LXRa/RXRa on the association of GR to
endogenous G6Pase and GILZ GREs in chromatin immunopre-
cipitation (ChIP) assays (Fig. 6B). In HeLa cells, GR bound to
G6Pase and GILZ GREs in a dexamethasone-dependent fashion.
Over-expression of LXRa along with RXRa strongly inhibited
this dexamethasone-mediated association of GR to G6Pase GREs
in a dose-dependent fashion (Fig. 6B, left upper panel), while it
demonstrated a weaker suppressive effect on the association of GR
to GILZ GREs, also in a dose-dependent fashion (Fig. 6B right
upper panel). When we used anti-LXRa antibody for pull-down of
protein/DNA complexes, some background precipitation of
LXRa to G6Pase, but not GILZ, GREs was observed in the
absence of dexamethasone (Fig. 6B, left and right middle panels,
white bars). RXRa was more obviously co-precipitated both with
G6Pase and GILZ GREs by anti-RXRa antibody in the absence
of dexamethasone (Fig. 6B, left and right lower panels, white bars).
Dexamethasone weakly attenuated co-immunoprecipitation of
LXRa or RXRa with G6Pase GREs, while it strongly suppressed
RXRa co-immunoprecipitation with GILZ GREs. Over-expres-
sion of LXRa/RXRa competed with dexamethasone-induced
inhibition of their binding with G6Pase and GILZ GREs (Fig. 6B,
left and right middle and lower panels). Pull-down with negative
control IgG did not show any difference in the precipitation of
Figure 5. GW3965 alters dexamethasone-induced mRNA expression of its responsive genes in rat liver in microarray analysis. A, B
and C: GW3965 modulates the transcriptional activity of a fraction of dexamethasone-responsive genes. Venn diagrams demonstrating the number of
genes regulated by dexamethasone (Dex) and/or GW3965 (A), Dex and/or Dex+GW3965 (B) and GW3965 and/or Dex+GW3965 (C). The common
biologic pathways regulated independently by Dex or GW3965 are also demonstrated in the right side of panel A. D. The 72-hour GW3965 treatment
does not alter GR protein levels in the rat liver. Tissue lysates were prepared from rat livers treated with indicated compounds. GR (upper panel) and b-
actin (lower panel) were visualized with their specific antibodies in Western blots. E. The number of genes regulated by Dex and GW3965 in respective
biologic pathways is shown. Nomenclatures of the demonstrated biologic activities are based on the ontology of the Gene Ontology: http://www.
geneontology.org. F. GW3965 does not influence mRNA expression of dexamethasone-suppressive genes in rat livers. Total RNA was harvested from
rat livers and mRNA levels of Ccl9 (left upper panel), Cxcl12 (right upper panel) and H6pd (lower panel) were measured with the SYBR-Green real-time
PCR. Bars represent mean 6 S.E. values of the fold induction of mRNA expression. *: p,0.01, n.s.: not significant between the two conditions
indicated. Dex: dexamethasone.
doi:10.1371/journal.pone.0026751.g005
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shown). We also found association of LXRa and RXRa on
G6Pase, but not GILZ, GREs in HepG2 cells (data not shown),
consistent with our results demonstrating the suppressive effect of
LXRa/RXRa on GR transcriptional activity in these cells (Fig. 3).
Our data suggesting that LXRa might impair GR activity by
competing with GR for GRE binding highlights a probable role of
the LXRa DBD. Thus, we examined the effect of a series of
LXRa mutants on GR-induced transcriptional activity in
HCT116 cells together with their binding to G6Pase GREs in
ChIP assays. Expression of such LXR mutants from the plasmids
employed was previously reported [38]. We found that the
repressive effect of LXRa on GR-induced transcriptional activity
was associated with the presence of its DBD, while this domain of
LXRa was critical for binding to the GREs (Fig. 6C), These results
indicate that LXRa competes with GR for binding to GREs and
subsequent activation of transcription via its DBD.
To further investigate the mechanism by which LXRa/RXRa
reduce the binding of GR to GREs, we performed gel mobility
shift assays using nuclear extracts from HeLa cells and
32P-
radiolabeled classic consensus GRE wild type (wt) or G6Pase GRE
wt (Fig. 6D, left and right panels, respectively). Under the
dexamethasone treatment, we identified two protein(s)-DNA
complexes A and B for these GREs. The stable protein-DNA
complex A (Fig. 6D, complex A, lanes 2 and 10) was produced as a
result of GRE sequence-specific binding to GR, since the presence
of anti-hGR antibody produced a supershift of the complex
(Fig. 6E) and the addition of 50-fold excess of cold classic
consensus GRE wild type (wt) or G6Pase GRE wt completely
abolished it, while both classic consensus GRE mutant (mut) and
G6Pase GRE mut, failed to do so (Fig. 6D, complex A in lanes 3, 5,
11 and 12, and complex A in lanes 4 and 13, respectively). In
contrast, the complex B formed with radiolabeled classic consensus
GRE wt did not indicate specific binding since both cold wild type
and mutated GREs of the classic as well as the G6Pase type
abolished it (Fig. 6D, complex B in lanes 3, 4 and 5). However,
complex B formed with G6Pase GRE wt might represent specific
binding of GR with this GRE, as G6Pase-GRE mut failed to
abolish it (Fig. 6D, complex B in lane 13). Addition of recombinant
LXRa/RXRa proteins to the nuclear extracts clearly decreased
the band intensity of complex A produced with radiolabeled classic
and wt G6Pase GREs (Fig. 6D, lanes 6 to 7 and lanes 14 to 15). The
decrease of GR association to its classic GREs was dose-dependent
on the amounts of LXRa/RXRa (Fig. 6F, upper panel, compare
lanes 3 to 5 and 7, and lower panel, compare columns 3 to 5 and 7).
When GW3965 were added to the nuclear extracts, a significant
decrease in GR binding to its classic radiolabeled GRE was
observed both in the presence or absence of recombinant LXRa/
RXRa (Fig. 6F, upper panel, compare lanes 3 to 4; 5 to 6 and 7 to 8
and lower panel, compare columns 3 to 4; 5 to 6; 7 to 8). Furthermore,
the incubation of classic GREs with recombinant LXRa/RXRa
proteins in the absence of nuclear extracts developed a new
protein(s)-DNA complex C, with similar migration properties as
complex C in Fig. 6D (lanes 9, 17 and 18), indicating that LXRa
and/or RXRa made a complex with radiolabeled classic and wt
G6Pase GREs. Addition of GW3965 treatment enhanced the
binding of LXRa/RXRa to the classic GRE (Fig. 6G, compare
lane 2 to 3), whereas the presence of anti-hLXRa antibody resulted
in a supershift of complex C (Fig. 6G, lane 4). These results indicate
that LXRa/RXRa bind to GREs and decrease the association of
GR to its GREs by competing with GR.
Discussion
We demonstrated that ligand-activated LXRs regulated GR-
induced transcriptional activity in a gene-specific fashion. This
activity of the LXRs appeared to be more on the transactivating,
and less on the transrepressing actions of glucocorticoids. This
interaction was observed in vivo in the regulation of circulating
glucose levels as an end-biological marker, as well as in the mRNA
expression of G6Pase, a key enzyme in glucose metabolism, in
both rat and mouse livers. In microarray analysis, the mutual
effects between the LXRs and the GR were observed primarily
from the direction of the former towards the latter. Consistent with
Table 1. mRNA Expression of Selective Glucocorticoid-responsive Genes in the Liver of Rats Treated with Dexamethasone in the
Absence or Presence of GW3965.
Protein Gene symbol Log ratio Dex* Log ratio Dex+GW3965*
Stem cell factor Scf 22.350 22.639
Chemokine (C-C motif) ligand 9 Ccl9 21.141 21.172
Interleukin 33 Il33 22.402 22.282
Chemokine (C-X-C motif) ligand 12 Cxcl12 22.205 21.599
Cyclin D1 Ccnd1 22.435 21.131
Cytokine inducible SH2-containing protein Cish 22.008 Not significant
6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 Pfkfb1 2.244 1.732551669
Solute carrier family 2 (facilitated glucose/fructose transporter),
member 5
Slc2a5 1.155 1.336
Glucose-6-phosphatase G6pc 1.473 Not significant
Hexose-6-phosphate dehydrogenase (glucose-1-dehydrogenase) H6pd 1.206 Not significant
Serine dehydratase Sds 3.521152 1.778876
Lipin 1 Lpin1 3.052642 1.49767
Interferon-induced protein 44 Ifi44 1.945108 2.775536
29-59 Oligoadenylate synthetase 1A Oas1a 3.992291 4.477496
Dex: dexamethasone.
*: Results demonstrated were sorted from those of the microarray analyses.
doi:10.1371/journal.pone.0026751.t001
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e26751Figure 6. LXRa/RXRa attenuates the association of GR to GREs in vitro and in vivo. A. Upper panel: LXRa/RXRa suppresses association of the
GR to its classic consensus GRE in vitro. HeLa cells were transfected with pCMX-hLXRa and pCMX-hRXRa, or their carrying plasmid pCMX, and were
treated with or without 10
26 M dexamethasone for 2 hours. Nuclear extracts were harvested from the cells and the binding activity of GR to GREs
was evaluated in the presence or absence of wild type (wt) or mutant (mut) GRE oligonucleotides (Oligos) using the TRansAM
TM GR kit (Active Motif).
Bars represent mean 6 S.E. values of the absorbance at 450 nm in the presence or absence of 10
26 M of dexamethasone. *: p,0.01, compared to the
condition transfected with the control plasmid in the presence of dexamethasone and in the absence of GRE Oligos or between the two conditions
indicated. Dex: dexamethasone. Lower panel: Overexpression of LXRa/RXRa does not influence dexamethasone-induced translocation of GR from the
cytoplasm into the nucleus. Nuclear extracts obtained from HeLa cells were run on 4–20% SDS-PAGE gels, blotted to nitrocellulose membranes and
GR (upper panel: nuclear GR, middle panel: whole cell GR) and hHSP4 (lower panel) were visualized with their specific antibodies in Western blots. B.
LXRa/RXRa overexpression differentially affects the association of GR to its GREs in ChIP assays. HeLa cells were transfected with the empty control
pCMX vector, or pCMX-hLXRa and -hRXRa, treated with or without 10
26 M dexamethasone, and ChIP assays were performed using anti-hGRa, anti-
hLXRa and anti-hRXRa antibodies. Bars represent mean 6 S.E. values of the fold precipitation of G6Pase GREs (left panel) or GILZ GREs (right panel)
determined in the SYBR Green-based real-time PCR. *: p,0.01, n.s.: not significant, compared to the condition transfected with the control plasmid in
the presence of dexamethasone or between the two conditions indicated. Dex: dexamethasone, IP: immunoprecipitation. C. DBD of LXRa confers
LXRa-mediated repression of GR transcriptional activity and binding to G6Pase GREs. HCT116 cells were transfected with pRShGRa together with
pMMTV-Luc and pGL4.73[hRluc/SV40], pCMX-hRXRa and the pCDNA3-6myc plasmid expressing wild type LXRa (1–447) or indicated LXRa mutants.
Cells were incubated in the presence (black columns) or absence (white columns) of 10
26 M dexamethasone. Using aliquots of cell lysates, luciferase
assays were performed. ChIP assays were also performed by treating cells with 4% formaldehyde, and by precipitating LXRa/G6Pase GREs with anti-
Myc-antibody. Bars represent mean 6 S.E. values of the firefly luciferase activity normalized for the renilla luciferase activity (left panel) or of the fold
precipitation of G6Pase GREs (right panel) determined in the SYBR Green-based real-time PCR in the presence or absence of 10
26 M dexamethasone.
*: p,0.01, n.s.: not significant, compared to the condition treated with dexamethasone in the absence of LXRa/RXRa or between the two conditions
indicated. NTD: N-terminal domain, DBD: DNA-binding domain, LBD: ligand-binding domain. D, E, F, G. LXRa/RXRa heterodimer binds to classic
consensus and G6Pase GREs in gel mobility shift assays and reduces GR binding to its GREs. D. Nuclear extracts from HeLa cells or LXRa/RXRa
recombinant proteins were incubated with
32P-labeled classic consensus GRE (left panel) or G6Pase GRE (right panel) with dexamethasone (Dex) in the
presence or absence of an excess amount (50-fold molar excess) of unlabeled classic consensus GRE wild type (wt), GRE mutated (mut), G6Pase GRE
wt, or G6Pase GRE mut. E. Nuclear extracts from HeLa cells were incubated with
32P-labeled classic consensus GRE in the presence or absence of
dexamethasone (Dex) and in the presence or absence of anti-GR antibody (Anti-GR Ab). F. Nuclear extracts from HeLa cells were incubated with
32P-
labeled classic consensus GRE in the presence or absence of dexamethasone (Dex) and/or GW3965 under the presence of increased amounts of
LXRa/RXRa recombinant proteins (upper panel). The intensities of band A from 3 independent experiments including that shown in the upper panel
were measured with the image J software and fold GRE binding was calculated by comparing to control (lane 1) (lower panel). Bars represent mean 6
S.E. values of fold GRE binding from 3 independent experiments. *: p,0.01, compared to the conditions indicated. G. LXRa/RXRa recombinant
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ed with GR for binding to consensus, as well as G6Pase and GILZ
GREs in vitro and in vivo. These results were further confirmed by
gel mobility shift assays in which LXRa/RXRa recombinant
proteins were used to examine their interaction with classic or
G6Pase GREs. This unexpected regulatory mechanism was
previously observed with other nuclear receptors: RXRb and its
heterodimer partner peroxisome proliferator-activated receptor a
interact with the estrogen response elements and regulate the
expression of estrogen-responsive genes by competing with the
estrogen receptor a for these DNA sequences [39,40]. Although
we examined only few GREs, we expect that LXR/RXR may
bind GREs located in various glucocorticoid-responsive promoter
regions to differentially regulate GR-induced transcriptional
activity in a gene-specific fashion; this would explain at least in
part the changes observed in our transcriptome analysis using
microarrays.
LXRs are also known to repress actively some of their
responsive genes, such as the inducible nitric oxide synthase
(iNOS), by attracting corepressor NCoR [41,42]. We examined
the contribution of NCoR to LXR-mediated repression of GR-
induced transcriptional activity using transient transfection-based
reporter assays, but did not find an apparent cooperation between
NCoR and the LXRs (data not shown). Thus, attraction of
corepressors to GREs through LXRs/RXRs does not appear to be
contributory to LXR-mediated repression of GR transcriptional
activity.
GR-mediated transcriptional regulation is quite complex, with
some effects exerted via direct binding of GR to GREs and others
through protein-protein interactions with various transcription
factors and/or cofactors [11]. Although the former correlates
more with the transactivational than with the transrepressive
effects of glucocorticoids, while the latter with the transrepressive
rather than the transactivational activity of these steroids, this is
not exclusive [43,44]. We assume that such complex regulation of
GR transcriptional activity is reflected in our microarray-based
transcriptome analysis and our hypothesis is that activation of
LXRs prevents primarily GRE-mediated transactivation and
secondarily transrepression through competition between these
receptors and the GRs for binding to GREs or interacting with
other transcription factors. Indeed, the genes down-regulated by
dexamethasone and further regulated by GW3965 may contain
negative GREs through which the latter compound might have
attenuated the suppressive effect of dexamethasone. Further study
examining presence of negative GREs in the promoter regions of
LXR/RXR-influenced glucocorticoid-responsive genes is neces-
sary to verify this hypothesis.
During preparation of this manuscript, Patel et al. reported that
LXRb was required for some metabolic actions of glucocorticoids
in the mouse liver, playing a supportive role in glucocorticoid-
induced hyperglycemia and liver steatosis in LXRa/b
2/2 mice
[45]. Mechanistically, they demonstrated that dexamethasone-
induced binding of GR to GREs was attenuated in a gene-specific
fashion in the liver of LXRa/b
2/2 mice [45], suggesting that
endogenous LXRb facilitates association of ligand-activated GR to
GREs of some glucocorticoid-responsive promoters. In fact, before
this manuscript was published, we proactively found that deletion
of endogenous LXRa/b either by siRNA-mediated knockdown or
by gene knockout attenuated dexamethasone-induced mRNA
expression of the PEPCK gene. We, however, did not observe the
positive effect of LXRa/b on GR-induced stimulation on G6Pase
mRNA expression in contrast to the results demonstrated by this
group, suggesting that this effect of endogenous LXRa/b on GR
observed in the absence of LXR agonists is gene-specific. We do
not know the exact mechanisms of this activity of endogenous,
unliganded LXRa/b, but the complex promoter structure around
the GREs of the PEPCK gene may be in part responsible
[46,47,48]. However, once LXRs are activated by pharmacologic
amounts of their ligands, LXRs suppressed GR-induced tran-
scriptional activity of both the G6Pase and the PEPCK genes,
possibly by inhibiting binding of this receptor to GREs through
association with promoter regions of these genes. Taken together,
our results provide important information on the regulation of GR
actions by LXR ligands, while the results of Patel et al. and some of
ours indicate the physiologic importance of LXRs on this receptor
in the absence of ligands. Further intensive research will hopefully
elucidate the molecular mechanism(s) underlying this positive to
negative ‘‘switch’’ of the LXR activity on the GR in response to
LXR ligands.
Glucocorticoids are commonly used for the treatment of a great
variety of allergic, autoimmune and inflammatory diseases, such as
asthma, rheumatoid arthritis, systemic lupus erythematosus and
acute septic shock [12]. Numerous side effects are, however,
associated with long-term and systemic use of pharmacologic doses
of glucocorticoids, including increased gluconeogenesis, liposynth-
esis and insulin resistance, leading to development of metabolic
syndrome, i.e., central obesity, carbohydrate intolerance, diabetes
mellitus type 2 and dislipidemia, with consequent atherosclerosis
and atherosclerosis-associated cardiovascular diseases [12]. Al-
though, admittedly, this may appear simplistic, the glucocorticoid-
related metabolic side effects are generally correlated with the
transactivational properties of the GR, while its beneficial
immunosuppressive effects are associated with its transrepressive
actions [1,7]. In our hands, LXRs strongly prevented glucocor-
ticoid effects on glucose metabolism, e.g. on G6Pase mRNA
expression, by repressing the transactivating activity of the GR,
while no such effects were observed in the transrepressive actions
of this steroid receptor on a NF-kB-responsive reporter gene in
HCT116 cells (Fig. 2C). This specificity of the LXR effect on GR-
induced transcriptional activity was recently confirmed by another
group in the mouse spleen [45]. Thus, pharmacologic amounts of
LXR agonists, such as GW3965, might be of benefit to patients
receiving glucocorticoid treatment for allergic, autoimmune and
inflammatory diseases, by attenuating the metabolic side effects of
these steroids (Table 1). These results might also explain some
conditions associated with simultaneous activation of LXR- and
GR-mediated pathways. For example, patients with Cushing
syndrome demonstrate both elevated levels of circulating gluco-
corticoids and hyperlipidemia [49], while subjects in acute or
chronic stress or suffering from major depression, who demon-
strate elevations of serum cortisol levels due to activation of the
hypothalamic-pituitary-adrenal axis, develop components of the
metabolic syndrome, such as visceral adiposity, hypertriglyceride-
mia, hypercholesterolemia and low HDL cholesterol [8]. Elevated
circulating cortisol in these patients/subjects stimulates GR in
target tissues, while elevated concentrations of circulating
cholesterol and triglycerides, as well as their metabolites in local
tissues, activate LXRs, possibly mitigating the effects of glucocor-
ticoids. We hypothesize that activated GR increases glucose
production by stimulating the transcriptional rate of G6Pase, and
other enzymes, while the elevated LXR ligands suppress this GR
effect by competing with GR for binding to GREs, forming a local
proteins were incubated with
32P-labeled classic consensus GRE in the presence or absence of GW3965 and anti-LXRa antibody (Anti-LXRa Ab).
doi:10.1371/journal.pone.0026751.g006
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pharmacologic use of their ligands appears to stimulate this
intrinsic protective mechanism [16,17]. Likewise, patients with
anorexia nervosa who demonstrate elevated cortisol levels and
reduced circulating cholesterol and triglycerides due to chronic
stress and reduced food intake [50], may be associated with
elevated GR transcriptional activity particularly in glucose
metabolism due to attenuation of LXR-mediated repression on
GR, which ultimately stimulates glucose production to counteract
the hypoglycemia caused by reduced nutritional intake.
In our microarray analysis, dexamethasone and GW3965
regulated mRNA expression of a similar cluster of genes
implicated in the inflammatory and immune response (Fig. 5A).
These results are consistent with the previous report, which
demonstrates GR and LXRs have an additive inhibition to a large
number of functionally related inflammatory genes by intervening
multiple, but distinct components of the Toll-like receptor 4
signaling pathway [51]. Thus, our results together with this
previous report suggest that the simultaneous administration of
LXR ligands may benefit the immunosuppressive effect of
glucocorticoids in the treatment of allergic, autoimmune and
inflammatory diseases. There is a caveat, however; some LXR
agonists may also induce lipogenesis and increase triglyceride
levels through induction of hepatic SREBP-1c gene expression
[15]. Therefore, a challenge for the future will be to develop a new
class of LXR ligands that will conserve a gene-specific effect on
suppressing GR transcriptional activity, but in a selective manner,
targeting LXRb but not LXRa, as the latter plays an essential role
in LXR agonist-mediated development of hypercholesterolemia
[52].
In conclusion, we found that pharmacologic activation of LXRs
suppresses GR-induced transcriptional activity by competing with
GR for binding to GRE DNA sequences in a gene-specific fashion.
Our results suggest that agonists for LXRs may be useful in
preventing the adverse metabolic actions of glucocorticoids
associated with chronic excess secretion, as in endogenous Cushing
syndrome or chronic stress, or prolonged therapeutic use of
pharmacologic doses [11,12].
Materials and Methods
Plasmids and reagents
pCMX-hLXRa, -hRXRa, -mLXRb and -mRXRa and
pRShGRa, which express human (h) and mouse (m) LXRa and
RXRa, and hGRa respectively, were all gifts from Dr. R.M.
Evans (Salk Institute, La Jolla, CA). pCDNA3-6myc plasmids
expressing the full-length human LXRa (amino acids 1–447) or its
truncated forms consisting of amino acids 1–163, 1–127, 98–163
or 164–447 were generous gifts from Dr. D. Kardassis (Founda-
tion of Research and Technology of Hellas, Crete, Greece).
pCMX, which is a carrier plasmid for hLXRa, hRXRa, mLXRb
and mRXRa and was used as a negative control for these
plasmids, and pGL4.73[hRluc/SV40], which expresses the renilla
luciferase under the control of the simian virus 40 promoter, were
purchased from Promega Corp. (Madison, WI). pMMTV-luc,
pGILZ-luc and pPEPCK-luc plasmids, which express the firefly
luciferase under the control of the indicated glucocorticoid-
responsive promoters, were gifts from Drs. G.L. Hager (National
Cancer Institute, Bethesda, MD), M. Pallardy (Institut National de
la Sante ´ et de la Recherche Medicale (INSERM), Paris, France)
and D.K. Granner (Vanderbilt University Medical School,
Nashville, TN), respectively. pRSV-RelA (p65) and pRSV-NF-
kBI (p50), which respectively express p65 and p50 component of
the nuclear factor-kB (NF-kB), were obtained from NIH AIDS
Research and Reference Reagent Program (Germantown, MD).
(kB)3-Luc, which expresses the firefly luciferase under the control
of three kB-responsive elements (REs), was reported previously
[53]. Recombinant hLXRa and hRXRa proteins were purchased
from Active Motif (Carlsbad, CA). Anti-hGRa, anti-hLXRa, anti-
hLXRa/b, anti-hRXRa, anti-human heat shock protein 4
(hHSP4) and rabbit control IgG antibodies were purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Primers for
hLXRa and b used in SYBR Green Real-Time PCR assays,
siRNAs targeting hLXRa, hLXRb or the control siRNA for
luciferase GL2 were purchased from Qiagen (Valencia, CA).
Dexamethasone, T0901317, GW3965 and 22-R-HC were
purchased from Sigma-Aldrich (St Louis, MO).
Cell cultures and transfections
Human hepatoma HepG2, human colon cancer HCT116 and
the human cervical cancer HeLa cells were all purchased from
American Type Culture Collection (Manassas, VA).
The human colon cancer HCT116 cells were cultured in
McCoy’s 5A medium supplemented with 10% fetal bovine serum
(FBS) and 100 U/mL of penicillin and 100 mg/mL of streptomy-
cin. The human cervical cancer HeLa and the human hepatoma
HepG2 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) with the same supplements. HCT116 cells do
not express endogenous GR, while HeLa and HepG2 cells have
the endogenous functional GR [20]. Cells were maintained in 5%
CO2 at 37uC. For reporter assays, HCT116 cells were transfected
with lipofectamine 2000
TM (Invitrogen, Carlsbad, CA) with
different amounts of the indicated plasmids, together with
0.5 mg/mL of pMMTV-Luc, pPEPCK-Luc, pGILZ-Luc or kB3-
Luc vector and 0.1 mg/mL of pGL4.73[hRluc/SV40] in 12-well
plates. Empty vectors were used to maintain the same amounts of
transfected DNA. One day after the transfection, 10
26 Mo f
dexamethasone and/or GW3965, T0901317 and/or 22-R-HC
were added to the medium and the cells were further cultured for
24 hours. The cells were then harvested, and the firefly and renilla
luciferase activities were measured using the dual-luciferase
reporter assay system (Promega Corp.) in the GlowMax
luminometer (Promega Corp.) according to the manufacturer’s
instructions. The relative luciferase activity (RLA) was calculated
(light units from the firefly luciferase assay divided by the light
units from the renilla luciferase assay) to correct for transfection
efficiency.
HepG2 cells were transfected with the siRNAs indicated using
the Nucleofector system (Reagent V and program T-28) (Amaxa
GmbH, Cologne, Germany). Twenty-four hours after transfection,
10
26 M of dexamethasone (Dex) and/or GW3965 were added to
the culture media. The following day, the cells were lysed and used
for purification of total RNA using the RNeasy Mini Kit (Qiagen,
Valencia, CA).
SYBR Green-based real-time PCR
Total RNA was reverse transcribed into cDNA, and real-time
PCR was performed in triplicate using the SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA) in a 7500 Real-
time PCR system (Applied Biosystems), as previously described
[54,55]. Primer pairs used for the reactions are shown in Table 2.
Obtained cycle threshold (Ct) values of the target genes were
normalized for those of RPLP0 or b-actin and their relative
mRNA expression was demonstrated as fold induction over the
baseline. The dissociation curves of primer pairs used showed a
single peak and samples after PCR reactions had a single expected
DNA band in agarose gel analysis (data not shown).
LXRs Regulate GR Transcriptional Activity
PLoS ONE | www.plosone.org 12 March 2012 | Volume 7 | Issue 3 | e26751Western blots
Proteins lysates and nuclear proteins from HepG2, HeLa cells
or rat livers were prepared using the Nuclear Extract Kit (Active
Motif), and were run on 4–20% SDS-PAGE gels. Separated
proteins were blotted to nitrocellulose membranes. hGR, hLXRa,
hLXRa/b and hHSP4 were visualized with anti-hGRa, anti-
hLXRa, andti- hLXRa/b and anti-hHSP4 antibodies, respec-
tively.
Treatment of animals with dexamethasone and/or
GW3965
Ethics statement: The following animal studies were approved by
the NICHD Animal Care and Use Committee (protocol numbers:
ASP 07-018 for the rat studies and ASP 09-009 for the mouse
studies).
Wild type and LXRa/b knockout mice were generous gifts
from Dr. D. Mangelsdorf (University of Texas Southwestern
Medical Center, Dallas, TX). For each experiment, 4 male
Sprague-Dawley rats (180–200 g), 4 wild type or 4 LXRa/b
knockout mice were orally gavaged for three days with GW3965
prepared in 1% Tween 80, 0.5% hydroxypropyl methylcellulose,
20 mM Na2HPO4 and 20 mM NaH2PO4 (50 mg/kg animal).
Another set of animals were also orally gavaged with the same
volume of the vehicle control (1% Tween 80, 0.5% hydroxypropyl
methylcellulose, 20 mM Na2HPO4 and 20 mM NaH2PO4). On
the third day, GW3965 or its vehicle control was administered first
to the animals followed by an intra-muscularly injection of
dexamethasone (1.5 mg/kg) or physiologic saline in two animals
from each group. Twenty-four hours after the injection, levels of
blood glucose were measured in these rats using the Freestyle
GlucoMeter (Abbott Laboratories, Abbott Park, IL) by sampling
blood from their tails. The animals were then euthanized using
CO2, and their livers were harvested for extraction and
purification of total RNA and proteins.
Microarray analysis
Five mg of total RNA purified from rat livers was used for
producing probes with the One-Cycle Target Labeling and
Control Reagents Kit (Affymetrix, Inc.). Rat Genome 230 2.0
Tiled Arrays (Affymetrix Inc.) were then labeled with the prepared
probes, washed and stained in the Affymetrix working station
(Affymetrix, Inc., Santa Clara, CA). Detailed data analysis steps
were performed as previously described [20]. Briefly, all probe
level annotations on the chip were verified before performing
analysis by re-mapping to current Unigene sequences database
(March 2006) and only those correctly mapped probes were used
for analysis. Samples were examined using the PM – only method
with MAS background signal subtraction [ref: www.bioconductor.
org]. One sample Student t-test was performed based on
comparisons of gene expression values (log ratio) of the same
probe set among all replicates with a critical value of p#0.05.
Candidate genes were identified by using the z distribution by
calculating the 95% cut off interval. The microarray data
discussed in this publication are MIAME compliant and the raw
data has been deposited in the Gene Expression Omnibus (GEO)
database of the National Center for Biotechnology Information
(www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO
Series accession number GSE29912.
In vitro binding assays for evaluation of the GR/GRE
association
HeLa cells were transfected with pCMX-hLXRa and -hRXRa
or pCMX using the lipofectamine 2000
TM. Twenty-four hours
after the transfection, cells were treated with 10
26 Mo f
dexamethasone for 2 hours, and nuclear extracts were prepared
using the Nuclear Extract Kit (Active Motif) in order to examine
binding of GR to classic GREs just after translocation of the GR
into the nucleus. In vitro binding assays for evaluating the
Table 2. Oligonucleotides Used in SYBR Green real-Time PCR
Analysis and Gel Mobility Shift Assays.
Protein name Primer sequence (59 to 39 orientation)
hG6Pase Forward TCATCTTGGTGTCCGTGATCG
Reverse TTTATCAGGGGCACGGAAGTG
hPEPCK Forward GAAAAAACCTGGGGCACAT
Reverse TTGCTTCAAGGCAAGGATCTCT
hGILZ Forward GATGTGGTTTCCGTTAAGC
Reverse CTCTCTCACAGCATACATCAG
hGRa Forward TGAAAATGGGTTGGTGCTTCTA
Reverse GACAAGAATACTGGAGATTTG
hABCG1 Forward AGCATCATGAGGGACTCGGT
Reverse GGAGGCCGATCCCAATGT
hRPLP0 Forward GAGGACCTCACTGAGATTCG
Reverse CTGGAAGAAGGAGGTCTTCTC
mG6Ppase Forward TTACCAAGACTCCCAGGACTG
Reverse GAGCTGTTGCTGTAGTAGTCG
mPEPCK Forward ATCTTTGGTGGCCGTAGACCT
Reverse GCCAGTGGGCCAGGTATTT
mb-actin Forward AAGCTGTGCTATGTTGCTCTAGACT
Reverse CACTTCATGATGGAATTGAATGTAG
ratG6Pase Forward GGCTCACTTTCCCCATCAGG
Reverse ATCCAAGTGCGAAACCAAACAG
ratPEPCK Forward CCCAGACTAGAGATCCTGACAGAAT
Reverse GCACAACGCTCTTTTCTTTTACC
ratRPLP0 Forward GAGAAGACCTCTTTCTTC
Reverse CAACATGTTCAGCAGTGTG
ratCCL9 Forward AGTCTGAAGGCACAGCAAGGGC
Reverse CGGCCTGGTACACCCACCAC
ratCXCL12 Forward TAGGCCACGCACGCAGCATC
Reverse GGCGTCTGACTCACACCTCTCAC
ratH6PD Forward GCGGTGGCTCAGATCCTGCC
Reverse CTGGCCCGACCTTCCGCATC
Classic GRE wt 59 AGCTGGTACAAACTGTTCTAGCT
39 TCGACCATGTTTGACAAGATCGA
Classic GRE mut 59 AGCTacgcgAgatgacgaTAGCT
39 TCGAtgcgcTctgctgctATCGA
G6Pase GRE wt 59 GCACTGTCAAGCAGTGTGCCCAAGTTAATAATT
39 CGTGACAGTTCGTCACACGGGTTCAATTATTAA
G6Pase GRE mut 59 GCACTacgcgGaAGgactaCCAAGTTAATAATT
39 CGTGAtgcgcCtTCctgatGGTTCAATTATTAA
G6Pase: glucose 6 phosphatase, PEPCK: phosphoenolpyruvate carboxykinase,
GILZ: glucocorticoid-inducible leucine zipper protein, GR: glucocorticoid
receptor, ABCG1: ATP-binding cassette sub-family G member 1, RPLP0: acidic
ribosomal phosphoprotein P0, GRE: glucocorticoid response element, h:
human, m: mouse, wt: wild type, mut: mutant – letters in lower cases indicate
the mutated basis.
doi:10.1371/journal.pone.0026751.t002
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TRansAM
TM GR Kit (Active Motif). Briefly, nuclear extracts
were added to a 96-well ELISA plate, which was provided by the
kit and had immobilized GRE oligonucleotides at the bottom of
each well. Free oligonucleotide, which encoded wild type or
mutant GREs, was added to some reactions to monitor specificity
of the assay. The plate was then incubated first with anti-GRa
antibody and second with horseradish peroxidase-conjugated
antibody, and binding activity of GR to GREs was estimated by
measuring absorbance at 450 nm with a reference wavelength of
655 nm in the Victor 3 (Applied Biosystems).
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed in HeLa, HepG2 and HCT116
cells. Briefly, cells were transfected with 0, 0.06 or 0.5 mgo f
pCMX-hLXRa and -hRXRa or pCDNA3-6myc pladmids using
the lipofectamine 2000
TM. The cells were exposed to either
10
26 M of dexamethasone or vehicle for 6 hours, and were
subsequently fixed, DNA and bound proteins were cross-linked for
10 min with 4% formaldehyde, and ChIP assays were performed
by co-immunoprecipitation of the DNA/protein complexes with
anti-hGRa, -hLXRa or -hRXRa antibodies or rabbit control IgG
(Santa Cruz Biotechnology, Inc.). We employed 6-hour incubation
with dexamethasone, as we found that this time point is sufficient
to detect accumulation of proteins on GREs in our assay system
(data not shown). The promoter region (2257 to 239) of the
endogenous G6Pase gene, which contains three functional GREs
[56], and that (21341 to 21209) of the endogenous GILZ gene
promoter that encloses one tandem GRE [24], were amplified
from the prepared DNA samples using the specific primer pairs
(G6Pase: Forward: 59-CAGACCCTTGCACTGCCAAGAAG-
CATG-39 and Reverse: 59-TATCCAGTATTCAGGTCAACC-
CAGCCC-39, and GILZ: Forward: 59-CCTTAACTTCATC-
CAAACTG-39 and Reverse: 59-CACCAGAAGGAGCAAGAG-
39) in the SYBR Green real-time PCR using the SYBR Green
PCR Master Mix and a 7500 Real-time PCR System. Obtained
Ct values of ChIP samples were normalized for those of
corresponding inputs, and their relative precipitation was
expressed as fold precipitation above the baseline.
Gel mobility shift assays
Double stranded oligonucleotides for classic or G6Pase GREs
[56] (Table 2) were radiolabeled with [c-
32P]dCTP using the T4
polynucleotide kinase (Invitrogen). Nuclear extracts from HeLa
cells (10 mg) or hLXRa/hRXRa recombinant proteins were
preincubated for 10 min at 4uC in the binding buffer [10 mM
HEPES pH 8.0, 0.1 mM EDTA, 2 mM DTT, 50 mM NaCl,
5 mM MgCl2, 50 mM KCl, 4 mM spermidine, 4% Ficoll, and
1 mg poly(dI-dC)] in the presence or absence of an excess amount
of unlabeled oligonucleotides encoding GRE wt, GRE mut,
G6Pase wt or G6Pase mut (Table 2). The corresponding
radiolabeled oligonucleotide probes (1610
5 cpm) were then added
to each sample, and the binding reaction was allowed to proceed
at room temperature for 15 min in the presence or absence of anti-
hGR or anti-hLXRa antibody. Nuclear proteins bound to
radiolabeled oligonucleotide probes were separated from free
probes on 6% DNA retardation gel (Invitrogen) at 100 V for
50 min, and the gel was dried and exposed to Biomax MR Film
(Eastman Kodak, St. Louis, MO) at 280uC.
Statistical analysis
All experiments were performed with duplicate or triplicate
samples and were repeated at least twice. Statistical analysis was
carried out by ANOVA, followed by Student’s t test with
Bonferroni correction for multiple comparisons or unpaired
Student t test with a two-tailed P value.
Supporting Information
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(DOC)
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